About us


Company overview

Novadip is transforming the lives of patients using its unique “3M3” tissue regeneration technology platform.

in 2013

Based on the scientific discoveries of Prof. Dr. Denis Dufrane, Novadip is a spin-off company from Université Catholique de Louvain (UCLouvain) and St. Luc University Hospital. The creation of Novadip was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.

Using our unique 3M3 tissue regeneration platform, which utilizes adipose-derived stem cells within a 3-dimensional extracellular matrix, to drive multiple product classes, Novadip’s mission is to provide innovative solutions for patients with limited or no effective treatment options.

At 45 and counting

Our growing team is experienced in all aspects of research, development and manufacturing of innovative therapies and dedicated to delivering life-changing solutions to patients with high unmet needs.

9 manuscripts

(basic science, in vivo preclinical & clinical results) in peer-review journals with 265 citations.

15 procedures for bone reconstruction

(6 tumor reconstruction, 5 bone non-union, 4 spine surgery) and 7 implantions for skin regeneration utilizing early versions of technology.



The company’s highly experienced management team has a deep knowledge of science, regulation and development pathways as well a proven track record in significant fundraising for regenerative medicine companies.


Board of


advisory board